X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Global pharma venturing beyond the US - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 9, 2010

    Global pharma venturing beyond the US

    No one can ever completely write off the US generics market. This is despite the intense competition there. After all, it is still the world's largest pharma market. And the opportunities in terms of drugs going off patent are huge. But most global players have realised that cannot entirely bank their fortunes on this highly competitive market. Opportunities elsewhere have to be explored. And in this quest for greener pastures, emerging markets and even Europe have caught the fancy of quite a lot of players. This is true of both innovators and generic companies alike.

    The lure of emerging markets (or semi regulated markets)
    Emerging markets have attractions for Indian and global pharma players for several reasons. Domestic companies earn revenues from branded generics in India and unbranded generics in the developed markets. But other emerging markets namely Asia, Russia, CIS, Africa and the like offer the best of both the worlds. Unlike in the US or Europe, generics here can be branded. In that respect, the environment is similar to that in India. But unlike India, medicines there are not subject to price control. And thus, the generics sold in the semi regulated markets have the potential to earn higher revenues and profits.

    For innovators, emerging markets offer them the chance to shore up their sagging business. Most of their blockbuster drugs are set to lose patents over the next few years. And their pipelines are not filling up fast to counter the decline in sales. The approval process has also become tougher. Thus, not many new patented drugs are expected to hit the markets in the future. Little wonder then that venturing into emerging markets has turned out to be the obvious solution.

    What are global players upto?
    Global innovators are entering the emerging markets especially India. This is either through acquisitions or partnerships. For instance, Daiichi Sankyo has acquired a majority stake in Ranbaxy. GSK Plc has allied with Dr. Reddy's to sell generic products in the semi regulated markets. Pfizer has entered into a partnership with Aurobindo Pharma.

    Not just innovators, top generic companies such as Teva, Mylan, and Watson have also made acquisitions in the last few years. All with the purpose of reducing their dependence on the US. Take the case of Teva. The Israeli generics player recently acquired the second largest generics company in Germany i.e., Ratiopharm. What is more, Teva plans to spend US$ 15-20 bn on acquisitions through 2015. The company aims to reduce the proportion of sales in the US from more than 60% at present to less than 50% by 2015.

    Thus, while the US will continue to form an integral part of the revenues and profits of global players, the sheen now lies elsewhere, in the less explored and less regulated markets that are Asia, Africa, Russia and to some extent Latin America.

     

     

    Equitymaster requests your view! Post a comment on "Global pharma venturing beyond the US". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    RANBAXY LAB SHARE PRICE


    Apr 1, 2015 (Close)

    TRACK RANBAXY LAB

    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MARKET STATS